FDA approves first nasal spray flu vaccine for at-home use

The FDA has approved AstraZeneca's treatment for use outside of healthcare facilities, but it will still require a prescription.

On Friday, the FDA approved the at-home use of FluMist, allowing those who are hesitant about needles to access a potentially lifesaving nasal spray flu vaccine more easily.

This marks the first time parents can administer the vaccine to children, and adults can use it themselves outside of a healthcare facility, although a prescription will still be necessary. FluMist is expected to be available from online pharmacies by next fall.

AstraZeneca, the producer, plans to launch a FluMist Home website where users can complete a questionnaire reviewed by a pharmacist before the treatment is shipped directly to them. The nasal spray will also remain available for in-office use. The current cost for a dose is approximately $35 to $45, depending on insurance coverage.

Dr. Peter Marks, director of the FDA’s vaccine center, emphasized that this approval offers a convenient option for families to receive a safe and effective flu vaccine. The FDA required AstraZeneca to demonstrate that the instructions for at-home use were clear and feasible, concluding that they were, but recommending that caregivers administer the spray to children aged 2 to 17.

Dr. Abraar Karan, an infectious disease specialist, noted that logistical barriers often prevent people from getting vaccinated, including the need for appointments and recovery time. He believes that the new at-home option will reduce these barriers and encourage more people to get vaccinated before flu season begins.

Copied